+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904662
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-obesity prescription drugs market is navigating a pivotal transition defined by therapeutic innovation, evolving patient needs, and increased global investment in obesity management. Senior leaders must understand how this sector’s fundamental shifts are shaping strategies, access, and long-term outcomes for healthcare providers, payers, and patients.

Market Snapshot: Anti-Obesity Prescription Drugs Market

The Anti-obesity Prescription Drugs Market grew from USD 6.71 billion in 2024 to USD 7.28 billion in 2025. It is expected to continue expanding at a CAGR of 8.15%, reaching USD 10.75 billion by 2030. These figures highlight substantial and sustained market momentum, reflecting rising prevalence rates and persistent unmet therapeutic needs. Market performance signals providers’ preference for pharmacological approaches that address complex metabolic pathways and deliver tangible health outcomes across diverse patient populations.

Scope & Segmentation

This report provides in-depth coverage of market dynamics, technological advancements, and strategic segmentation to support informed decision-making. Key segments and regional profiles include:

  • Drug Classes: Amylin analogs (Pramlintide), GLP-1 agonists (Dulaglutide, Exenatide, Liraglutide, Semaglutide), lipase inhibitors (Orlistat), serotonin receptor modulators (Locaserin).
  • Administration Routes: Injectables (auto-injectors, prefilled pens, vials and syringes), oral formats (capsules, tablets).
  • Distribution Channels: Offline and online models, including e-pharmacies and brick-and-mortar outlets.
  • End Users: Ambulatory care centers, home care settings, hospitals, specialty clinics (endocrinology, general practice, weight loss clinics).
  • Regions: Americas (with access points such as the United States, Canada, Brazil, Mexico, Argentina), Europe, Middle East & Africa (inclusive of Germany, UK, France, UAE, South Africa, and more), Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Key Companies: Major players covered include Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Roche Holding AG, and Boehringer Ingelheim International GmbH.

Key Takeaways for Strategic Decision-Makers

  • Clinical innovation is accelerating, with the pipeline emphasizing hormone analogs and receptor modulators that move beyond traditional lipase inhibitors and appetite suppressants.
  • Technology adoption, such as sustained-release formulations and smart dosing pens, is elevating real-world adherence and supporting outcome-driven care models.
  • Personalized medicine is redefining trial designs and segmentation, relying on genomic and phenotypic data to inform targeted treatment strategies and optimize efficacy.
  • Supply chains are adapting to changing tariff environments, prompting manufacturers to explore nearshoring and alternative sourcing strategies to reduce vulnerability.
  • Patient-centric distribution models and digital engagement platforms are broadening access, enabling remote monitoring, and supporting better adherence pathways across diverse care settings.
  • Pharmaceutical leaders are engaging in collaborative partnerships, M&A activity, and value-based contract negotiations to reinforce competitive advantages and strengthen market position.

Tariff Impact on Supply Chain and Pricing

New United States tariffs, implemented in 2025, are reshaping the cost structure and operational models within the anti-obesity prescription drugs sector. Elevated duties on imported active pharmaceutical ingredients have prompted companies to adjust sourcing strategies, consider nearshoring, and incorporate tariff contingencies into procurement contracts. These measures support greater supply continuity but also introduce new pressures on wholesale pricing, rebate mechanisms, and margin integrity. Proactive risk management and transparent value-based engagement with payers are now integral to maintaining access and efficiency.

Methodology & Data Sources

Our analysis employs a dual-phased approach: direct insights from leading endocrinologists, supply chain executives, and formulary decision-makers coupled with systematic secondary research. Regulatory filings, clinical trial data, proprietary databases, and peer-reviewed journals provide validation. All findings are reviewed by an independent advisory panel to ensure accuracy and relevance.

Why This Report Matters

  • Delivers actionable intelligence on evolving therapies, patient populations, and regulatory frameworks to guide strategy.
  • Supports operational resilience and informed risk management in the face of shifting global supply chain and tariff conditions.
  • Enables market leaders to tailor products, partnerships, and engagement models for maximum impact in a competitive, dynamic sector.

Conclusion

The anti-obesity prescription drugs market is characterized by innovation, adaptability, and patient-centric growth opportunities. This report empowers senior decision-makers to align strategy and operations to capture value and drive sustainable progress in a rapidly evolving environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of GLP-1 receptor agonists driven by obesity comorbidity outcomes
5.2. Real-world cardiovascular event reduction data boosting anti-obesity drug uptake
5.3. Formulation improvements enabling oral administration of injectable obesity therapies
5.4. Patient adherence challenges prompting digital health integration for weight management
5.5. Payers expanding coverage policies in response to long-term health cost savings evidence
5.6. Emerging competitive pipeline drugs targeting dual GIP and GLP-1 therapeutic pathways
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-obesity Prescription Drugs Market, by Drug Class
8.1. Introduction
8.2. Amylin Analogs
8.2.1. Pramlintide
8.3. GLP-1 Agonists
8.3.1. Dulaglutide
8.3.2. Exenatide
8.3.3. Liraglutide
8.3.4. Semaglutide
8.4. Lipase Inhibitors
8.4.1. Orlistat
8.5. Serotonin Receptor Modulators
8.5.1. Locaserin
9. Anti-obesity Prescription Drugs Market, by Administration Route
9.1. Introduction
9.2. Injectables
9.2.1. Auto-Injectors
9.2.2. Prefilled Pens
9.2.3. Vials And Syringes
9.3. Orals
9.3.1. Capsules
9.3.2. Tablets
10. Anti-obesity Prescription Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Anti-obesity Prescription Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Care Settings
11.4. Hospitals
11.5. Specialty Clinics
11.5.1. Endocrinology Clinics
11.5.2. General Practice Clinics
11.5.3. Weight Loss Clinics
12. Americas Anti-obesity Prescription Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Anti-obesity Prescription Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novo Nordisk A/S
15.3.2. Eli Lilly and Company
15.3.3. Pfizer Inc.
15.3.4. AstraZeneca PLC
15.3.5. Sanofi S.A.
15.3.6. GlaxoSmithKline plc
15.3.7. Johnson & Johnson
15.3.8. Merck & Co., Inc.
15.3.9. Roche Holding AG
15.3.10. Boehringer Ingelheim International GmbH
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCHAI
FIGURE 24. ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 25. ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCHCONTACTS
FIGURE 26. ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 133. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 136. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 137. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 138. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
TABLE 276. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2030 (USD MILLION)
TABLE 277. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
TABLE 280. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2030 (USD MILLION)
TABLE 281. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 288. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 289. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
TABLE 294. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2030 (USD MILLION)
TABLE 295. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 2

Samples

Loading
LOADING...

Companies Mentioned

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Pfizer Inc.
  • AstraZeneca PLC
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Roche Holding AG
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.75 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Obesity Treatment Market by Treatment Type (Pharmacotherapy, Surgical Procedures), Drug Class (Appetite Suppressants, GLP-1 Receptor Agonists, Lipase Inhibitors), Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030 - Product Image

Obesity Treatment Market by Treatment Type (Pharmacotherapy, Surgical Procedures), Drug Class (Appetite Suppressants, GLP-1 Receptor Agonists, Lipase Inhibitors), Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Weight Loss And Obesity Management Global Market Report 2025 - Product Image

Weight Loss And Obesity Management Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Obesity Market Report and Forecast 2025-2034 - Product Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Obesity: 68-Market Analysis and Sales Forecast - Product Image

Obesity: 68-Market Analysis and Sales Forecast

  • Report
  • 20 Pages
  • Global
From

About the Anti Obesity Prescription Drugs Market

The Anti-Obesity Prescription Drugs market is a segment of the healthcare industry focused on the development, production, and marketing of medication designed to combat obesity. These medications are intended for individuals who are unable to achieve weight loss through diet and exercise alone. Anti-obesity drugs work through various mechanisms, including appetite suppression, increased energy expenditure, and decreased nutrient absorption. The market encompasses a variety of drug classes, such as lipase inhibitors, serotonin receptor agonists, and others, each targeting different pathways related to weight regulation. The use of anti-obesity prescription drugs is typically recommended for those with a body mass index (BMI) above a certain threshold or for overweight individuals with weight-related health conditions such as diabetes or high blood pressure. The development of these pharmacological agents is guided by stringent regulatory standards to ensure their efficacy and safety. Market players invest in research and development to introduce more effective treatments with fewer side effects, as obesity remains a leading health concern. Several companies are key contributors to the Anti-Obesity Prescription Drugs market. Some of the well-known players include Novo Nordisk, GlaxoSmithKline, Roche, and Vivus, Inc. These companies are involved in manufacturing FDA-approved prescription drugs and are engaged in ongoing research to improve existing treatments and bring new solutions to the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.